Recalls Continue to Plague Johnson & JohnsonSep 13, 2013
Consumer healthcare products giant Johnson & Johnson has issued two recalls in the last week on drugs that were found to contain foreign matter that could have put the public at risk.
The New York Times reports that these recalls show that Johnson & Johnson still hasn’t fully recovered from quality-control problems it faced several years ago that led to the closing of a major manufacturing facility of over-the-counter drugs operated by one of its subsidiaries.
The one recall issued during the past week included liquid Motrin intended for infants. The liquid was found to contain small plastic particulate matter, about the size of a poppy seed. The recall of infant’s liquid Motrin included about 200,000 bottles of the product. Liquid Motrin is manufactured by McNeil Consumer Healthcare, a division of Johnson & Johnson, the New York Times reports.
According to our reports in the past, McNeil Consumer Healthcare was forced to shut its Pennsylvania manufacturing facility several years ago when federal health inspectors determined that quality-control standards were not being kept, which led to potentially unsafe drugs reaching the consumer level. Millions of major brands of over-the-counter drugs had to be recalled following these revelations.
The other recall recently issued by Johnson & Johnson was for Risperdal Consta, an injectable form of the antipsychotic drug. The recall was deemed necessary after evidence of mold was found in the drug, the New York Times reports.
Johnson & Johnson, of course, is also the parent company of DePuy Orthopaedics, the maker of the recalled ASR metal-on-metal hip implant. Thousands of Americans have already filed lawsuits against the company claiming that the recalled hip implant is defective and responsible for a litany of injuries and increased medical costs, based on our previous reports.